CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. The Company's purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
Type
Public
HQ
South Brunswick Township, US
Founded
2002
Size (employees)
65 (est)
Cytosorbents was founded in 2002 and is headquartered in South Brunswick Township, US
Report incorrect company information

Key People/Management at Cytosorbents

Phillip Chan

Phillip Chan

Chief Executive Officer and President
Kathleen Bloch

Kathleen Bloch

CFO
Vincent Capponi

Vincent Capponi

COO
Robert Bartlett

Robert Bartlett

Chief Medical Officer
Show more

Cytosorbents Office Locations

Cytosorbents has an office in South Brunswick Township
South Brunswick Township, US (HQ)
k 7 Deerpark Dr
Show all (1)
Report incorrect company information

Cytosorbents Financials and Metrics

Cytosorbents Revenue

Embed Graph
Cytosorbents's revenue was reported to be $15.15 m in FY, 2017 which is a 59% increase from the previous period.
USD

Revenue (FY, 2017)

15.2 m

Revenue growth (FY, 2016 - FY, 2017), %

59%

Gross profit (FY, 2017)

9.6 m

Gross profit margin (FY, 2017), %

63.6%

Net income (FY, 2017)

(8.5 m)

EBIT (FY, 2017)

(9.8 m)

Market capitalization (16-Aug-2018)

358.6 m

Closing stock price (16-Aug-2018)

11.4

Cash (31-Dec-2017)

17.3 m

EV

351.3 m
Cytosorbents's current market capitalization is $358.6 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

4.8 m9.5 m15.2 m

Revenue growth, %

99%59%

Cost of goods sold

2.2 m4 m5.5 m

Gross profit

2.6 m5.6 m9.6 m
USDFY, 2015FY, 2016FY, 2017

Cash

5.3 m5.2 m17.3 m

Accounts Receivable

648.9 k1.4 m2.2 m

Prepaid Expenses

511.9 k315.8 k416 k

Inventories

1.2 m834 k795.7 k
USDFY, 2015FY, 2016FY, 2017

Net Income

(8.1 m)(11.8 m)(8.5 m)

Depreciation and Amortization

113 k161.6 k218.3 k

Inventories

(671.3 k)340.4 k57.3 k

Accounts Payable

(83.2 k)2.1 m523.4 k
USDY, 2017

EV/EBIT

-35.7 x

EV/CFO

-54.4 x

Revenue/Employee

233.1 k

Debt/Equity

1 x

Debt/Assets

0.4 x

Financial Leverage

2.3 x

P/E Ratio

(35.6 )
Show all financial metrics
Report incorrect company information

Cytosorbents Online and Social Media Presence

Embed Graph
Report incorrect company information

Cytosorbents News and Updates

Report incorrect company information

Cytosorbents Company Life and Culture

Report incorrect company information